Last reviewed · How we verify
recombinant B-type, natriuretic peptide — Competitive Intelligence Brief
marketed
Natriuretic peptides
Natriuretic peptide receptor-A (NPR-A)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
recombinant B-type, natriuretic peptide (recombinant B-type, natriuretic peptide) — University of Texas Southwestern Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant B-type, natriuretic peptide TARGET | recombinant B-type, natriuretic peptide | University of Texas Southwestern Medical Center | marketed | Natriuretic peptides | Natriuretic peptide receptor-A (NPR-A) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Natriuretic peptides class)
- University of Texas Southwestern Medical Center · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant B-type, natriuretic peptide CI watch — RSS
- recombinant B-type, natriuretic peptide CI watch — Atom
- recombinant B-type, natriuretic peptide CI watch — JSON
- recombinant B-type, natriuretic peptide alone — RSS
- Whole Natriuretic peptides class — RSS
Cite this brief
Drug Landscape (2026). recombinant B-type, natriuretic peptide — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-b-type-natriuretic-peptide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab